277 related articles for article (PubMed ID: 16133434)
1. [The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview].
Sevecke K; Battel S; Dittmann RW; Lehmkuhl G; Döpfner M
Nervenarzt; 2006 Mar; 77(3):294, 297-300, 302-4 passim. PubMed ID: 16133434
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
3. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
Davids E; Gastpar M
Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
Simpson D; Plosker GL
Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
Simpson D; Plosker GL
CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
[TBL] [Abstract][Full Text] [Related]
6. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
Corman SL; Fedutes BA; Culley CM
Am J Health Syst Pharm; 2004 Nov; 61(22):2391-9. PubMed ID: 15581262
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
CNS Drugs; 2010 Jan; 24(1):85-8. PubMed ID: 20030421
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Stuhec M; Munda B; Svab V; Locatelli I
J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
12. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
13. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.
Christman AK; Fermo JD; Markowitz JS
Pharmacotherapy; 2004 Aug; 24(8):1020-36. PubMed ID: 15338851
[TBL] [Abstract][Full Text] [Related]
14. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
Prasad S; Steer C
Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
16. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.
Upadhyaya HP; Desaiah D; Schuh KJ; Bymaster FP; Kallman MJ; Clarke DO; Durell TM; Trzepacz PT; Calligaro DO; Nisenbaum ES; Emmerson PJ; Schuh LM; Bickel WK; Allen AJ
Psychopharmacology (Berl); 2013 Mar; 226(2):189-200. PubMed ID: 23397050
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
Cheng JY; Chen RY; Ko JS; Ng EM
Psychopharmacology (Berl); 2007 Oct; 194(2):197-209. PubMed ID: 17572882
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
Bushe CJ; Savill NC
J Psychopharmacol; 2014 Mar; 28(3):204-11. PubMed ID: 23438503
[TBL] [Abstract][Full Text] [Related]
20. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Prasad S; Harpin V; Poole L; Zeitlin H; Jamdar S; Puvanendran K;
Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
